Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice by Chu, Jin et al.
RESEARCH ARTICLE Open Access
Adeno-associated virus-mediated brain delivery
of 5-lipoxygenase modulates the AD-like
phenotype of APP mice
Jin Chu
1, Phillip F Giannopoulos
1, Carolina Ceballos-Diaz
2, Todd E Golde
2 and Domenico Pratico
1*
Abstract
Background: The 5-lipoxygenase (5LO) enzymatic pathway is widely distributed within the central nervous system.
Previous works showed that this protein is up-regulated in Alzheimer’s disease (AD), and that its genetic absence
results in a reduction of Amyloid beta (Ab) levels in the Tg2576 mice.
Here by employing an adeno-associated viral (AAV) vector system to over-express 5LO in the same mouse model,
we examined its contribution to their cognitive impairments and brain AD-like amyloid pathology.
Results: Our results showed that compared with controls, 5LO-targeted gene brain over-expression in Tg2576 mice
results in significant memory deficits. On the other hand, brain tissues had a significant elevation in the levels of
Ab peptides and deposition, no change in the steady state levels of amyloid-b precursor protein (APP), BACE-1 or
ADAM-10, but a significant increase in PS1, nicastrin, and Pen-2, three major components of the g-secretase
complex. Additional data indicate that the transcription factor CREB was elevated and so were the mRNA levels for
PS1, nicastrin and Pen-2.
Conclusions: These data demonstrate that neuronal 5LO plays a functional role in the pathogenesis of AD-like
amyloidotic phenotype by modulating the g-secretase pathway. They support the hypothesis that this enzyme is a
novel therapeutic target for the treatment and prevention of AD.
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Background
The enzyme 5-lipoxygenase (5LO) catalyzes the conver-
sion of arachidonic acid to 5-hydroxy-peroxy-eicosate-
traenoic acid (5-HPETE) and subsequently to 5-
hydroxy-eicosatetraenoic acid (5-HETE), which can be
then metabolized into different leukotrienes [1]. The
5LO is widely expressed in the central nervous system
(CNS), where it localizes mainly in neuronal cells. Its
presence has been documented in various regions of the
brain, including hippocampus and cortex, where signifi-
cant increase in its level has been associated with aging
[2-4]. Since aging is one of the strongest risk factors for
developing sporadic Alzheimer’s disease (AD), this path-
way has been involved in its pathogenesis. To this end,
5LO immunoreactivity is increased in hippocampi of
AD patients versus controls [5]; 5LO-targeted gene dis-
ruption or its pharmacologic inhibition resulted in a sig-
nificant reduction of Ab levels and deposition in the
brains of the Tg2576 mice, an animal model of AD-like
amyloidosis [6,7]. However, the specific mechanisms
involved in this biologic effect remain unclear.
In the current study, by employing an adeno-asso-
ciated viral (AAV) vector system to over-express 5LO in
the brain of Tg2576, we examined its contribution to
their cognitive impairments and the AD-like amyloid
pathology, and investigated the mechanism responsible
for it.
AAV-treated animals were tested for cognitive impair-
ments, and brain tissues assayed for Ab levels and APP
metabolism. The results show that AAV-mediated 5LO
brain gene transfer results in a worsening of their beha-
vioral deficits and a significant increase in the amount
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changes in Ab were not associated with any significant
modification of total APP, BACE-1 or ADAM-10 pro-
tein levels. By contrast, we observed that these brains
had a significant increase in the levels of the transcrip-
tion factor CREB, which then resulted in a significant
elevation of the mRNA and protein levels for the 3
major components of the g-secretase complex, i.e. PS1,
nicastrin and Pen-2.
Results
Cognitive deficits in animals treated with AAV2/1 vector
encoding 5LO
In the Y-maze, mice receiving the empty vector control
and the group treated with AAV2/1-5LO did not show
any significant difference in the total number of arm
entries, suggesting that there were no differences in the
general activity of these animals (Figure 1A). However,
the number of alternations for the Tg2576 mice receiv-
ing the AAV2/1-5LO was lower when compared with
their control group, and as a result the percentage of
alternations was significantly reduced (Figure 1B). In the
fear conditioning test, Tg2576 mice receiving the
AAV2/1-5LO had generally less percentage freezing
time in both the contextual and cued recall paradigms
when compared with their control group. However, this
difference reached statistical significance only in the
cued recall (Figure 1C, D). No effect of AAV2/1-5LO on
both paradigms was observed in wild type controls (Fig-
ure 1A-C).
Ab levels in animals treated with AAV2/1 vector encoding
5LO
A week after the behavioral tests, Tg2576 mice were
sacrificed and brain Ab levels and deposition were ana-
lyzed using both biochemical and immunohistochemical
methods. As shown in Figure 2A, we found that com-
pared with Tg2576 control mice receiving the empty
vector, the group treated with AAV2/1-5LO had a sig-
nificant increase in the amount of RIPA-soluble and
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Figure 1 AAV1/2-5LO over-expression modulates behavioral deficits of Tg2576 mice. A. Number of total arm entries for AAV1/2-5LO and
AAV-empty vector control treated Tg2576 and wild type (WT) mice. B. Contexual fear memory response in AAV1/2-5LO and empty vector
treated Tg2576 and wild type (WT) mice. C. Percentage of alternations between AAV-5LO and AAV-empty vector (*p < 0.01). D. Cued fear
memory response in AAV1/2-5LO and empty vector injected Tg2576 and wild type (WT) mice. Values represent mean ± SEM; *p < 0.01; n = 10
AAV1/2-5L0; n = 8 empty vector.
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Figure 2 AAV1/2-5LO over-expression modulates brain Ab peptides levels and deposition in Tg2576 mice. A. RIPA-soluble (left panels)
and formic acid extractable (right panels) Ab1-40 and Ab1-42 levels in cortex of Tg2576 receiving empty vector (CTL) or AAV1/2-5LO gene were
measured by sandwich ELISA. (n = 8 for CTL, and n = 10 for AAV-5LO; *p < 0.05). B. Representative sections of brains from Tg2576 mice
receiving AAV1/2-5LO or empty vector (CTL) immunostained with 4G8 antibody. C. Quantification of the area occupied by Ab immunoreactivity
in brain of Tg2576 mice receiving AAV1/2-5LO or empty vector (CTL) (*p < 0.05). Values represent mean ± SEM (n-8 CTL; n = 10 AAV-5LO).
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were confirmed when a pan-Ab antibody, 4G8, was used
to detect the Ab immunoreactive areas in the brains of
these mice (Figure 2B, C).
Over-expression of 5LO modulates neuroinflammation
5LO is an enzyme whose activation and expression
levels have been linked to an increased inflammatory
response [1]. Since neuroinflammation is also an impor-
tant feature of this AD-like amyloidosis model, next we
investigated the effect of 5LO over-expression on micro-
glia and astrocytes. As shown in Figure 3D and 3E, mice
over-expressing 5LO had a significant increase in the
immunoreactivity for GFAP, a marker of astrogliosis,
and CD45, a marker of microgliosis.
Over-expression of 5LO modulates the g-secretase pathway
Transgene expression was confirmed by immunoblotting
and immunohistochemical approaches. Thus, we observed
that 5LO protein levels were significantly higher in
Tg2576 mice receiving the AAV2/1-5LO than the ones
treated with the empty vector (Figure 3A, B). Immunohis-
tochemistry analysis of the same brains showed a signifi-
cant increase in neuronal 5-LO immunoreactivity when
compared with mice injected with empty vector (Figure
3C). A direct correlation between Ab levels and 5LO
expression in Tg mice receiving AAV2/1-5LO was
observed (Figure 3D). Since Ab is the final product of the
proteolytic processing of its own precursor, the Ab precur-
sor protein (APP), next we investigated whether this treat-
ment was associated with an alteration of its expression
levels. As shown in Figure 3A, B, we found that there was
no difference in total APP levels between the two groups
of mice. To assess the effect of AAV2/1-5LO on APP pro-
cessing we investigate the steady state levels of main
enzyme proteases involved: a-secretase (ADAM-10), b-
secretase (BACE-1), and the four components of the g-
secretase complex by western blot analysis. As shown in
Figure 3, no significant differences in the levels of ADAM-
10, BACE-1, sAPPa,s A P P b, and CTFs were observed
between the two groups of mice. By contrast, we observed
that mice receiving the vector encoding for 5LO had a sig-
nificant increase in the steady state levels of three of the
four components of the g-secretase complex, PS1, Nicas-
trin, Pen-2, but not APH-1 (Figure 3A, B). In addition, we
found no differences between the two groups of mice
when the steady-state levels of two main Ab degrading
enzymes, neprilysisn and IDE, as well as apolipoprotein E
(apoE), an Ab chaperone, were assayed (Figure 3A).
Over-expression of 5LO modulates transcription of the g-
secretase complex
The data collected so far suggest that over-expression of
5LO could modulate the g-secretase complex expression
at the transcriptional or translational level. Since pre-
vious studies have shown that pharmacological blockade
of 5-LO reduces activation of the transcriptional factor
CREB and then regulate the transcription of the g-secre-
tase complex [7], we wanted to test if this was also the
case in our system. Compared with control mice, we
found that Tg2576 mice treated with AAV encoding for
5LO showed a statistically significant increase in the
steady state levels of total CREB and its phosphorylated
form at Ser133 (Figure 4A, B). However, the same treat-
ment did not significantly affect the steady state levels
of Sp1, another transcription factor (Figure 4A, B).
Additionally, quantitative real time RT-PCR analyses
showed that the same mice had a significant increase in
the mRNA levels for PS1, nicastrin and Pen-2 but not
for APH-1 (Figure 4C).
Discussion
The data presented in this study demonstrate that intra-
cranial virally-mediated gene transfer of 5LO signifi-
cantly worsens cognitive deficits, brain Ab formation
and deposition in the Tg2576 mouse model of AD and
thereby provide strong new evidence that this enzymatic
pathway is a modulator of amyloidogenesis in vivo.
Previous studies reported that 5LO expression is
increased in rodent brain with aging, especially in the
cortex and hippocampus, two regions which are known
to be more susceptible to neurodegeneration. This origi-
nal observation represented the basis for the hypothesis
that a biologic link exists between 5LO and neurodegen-
erative diseases, whose strongest risk factor is aging. In
line with it, 5-LO immunoreactivity is increased in hip-
pocampi of AD patients versus controls [5], and poly-
morphism of the 5-LO promoter can influence the age
of onset of the disease [8]. Previous work from our
group have shown that genetic deficiency or pharmaco-
logic inhibition of 5-LO results in a significant ameliora-
tion of the brain amyloidotic phenotype of the Tg2576,
suggesting for the first time a functional role for this
enzymatic pathway in modulating Ab formation and
deposition [6,9].
In the present study, we wanted to further extend
this observation by using a virally mediated somatic
gene transfer approach to increase 5LO expression
levels in the central nervous system of APP mice
allowing examination of its specific contribution to
their cognitive deficits and brain AD-like amyloid
pathology. As the somatic brain transgenic technique
employed largely results in neuronal transduction, in
these studies we examined the effects of 5-LO expres-
sion in neurons.
Herein, we demonstrate that its over-expression
results in significantly higher Ab peptides production
and deposition in the brains of Tg2576 mice, which
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Figure 3 AAV1/2-5LO over-expression alters brain APP metabolism via the g-secretase pathway in Tg2576 mice. A.R e p r e s e n t a t i v e
western blots of 5LO, APP, ADAM-10, BACE-1, sAPPa, sAPPb, CTFa, CTF-b, PS1, Nicastrin, APH-1, Pen-2, apoE, neprilysin, IDE in brain
homogenates from Tg2576 mice receiving AAV1/2-5LO or empty vector (CTL). B. Densitometric analyses of the immunoreactivities to the
antibodies shown in the previous panel. Values represent mean ± SEM (* p < 0.01). C. Representative sections of different brain regions from
Tg2576 mice receiving AAV1/2-5LO or empty vector (CTL) immunostained for 5-LO (× 20 magnification). D. Correlation between levels of 5LO
protein and RIPA soluble Ab 1-40 peptides (r
2 = 0.61, p = 0.0003). E. Representative brain sections from Tg2576 receiving AAV1/2-5LO or empty
vector (CTL) immunostained for GFAP and CD45 (× 20 magnification). F. Quantitative analysis of the immunoreactivity for GFAP and CD45 in the
same animals.(*p < 0.004).
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and astrocytes.
In this experimental setting we observed that the
increased 5LO expression had no effect on APP levels.
By contrast, we observed that the APP proteolyitc pro-
cessing germane to Ab production was altered by the
treatment. Thus, we found that while both ADAM-10
and BACE1 were not altered, the g-secretase complex
was significantly increased, suggesting a direct involve-
ment of this proteolytic pathway in the observed biolo-
gical effect of somatic 5-LO gene transfer. No significant
changes were detected in the Ab catabolic pathway,
since no differences between the two groups were
observed for neprilysin, IDE and apoE levels.
Besides these biochemical changes in the brains of the
animals, we observed a worsening of their working and
learning memory performances.
The first aspect was tested in the Y-maze paradigm
which by recording spontaneous alternation behavior
has previously been shown to be a reliable, and noninva-
sive test to assess some of the cognitive changes in the
Tg2576 [10-12]. In the current study, we observed that
o v e r - e x p r e s s i o no ft h e5 L Oi nt h eb r a i no ft h e s em i c e
while did not alter the number of entries, which reflects
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Figure 4 AAV1/2-5LO over-expression modulates CREB levels and transcription of the g-secretase complex in the brains of Tg2576
mice. A. Levels of total CREB and its phosphorylated form at Ser133 and Sp1 in the cortex of Tg2576 receiving AAV1/2-5LO or empty vector
(CTL) assayed by western blot analyses. B. Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. C.
Relative mRNA levels for PS1, Nicastrin, APH-1 and Pen-2 in the cortex of Tg2576 mice receiving AAV1/2-5LO or empty vector (CTL), as
determined by real-time quantitative RT-PCR amplification. Values represent mean ± SEM (*p < 0.01).
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percentage of alternations during the test. These find-
ings suggest that mice over-expressing 5LO have impair-
ments in their immediate working memory.
In addition, animals were also tested in their learning
memory ability by the fear conditioning paradigm. In accor-
dance with the Y-maze we observed that in general AAV1/
2-5LO treated mice performed worse than their controls.
However, we observed a statistically significant difference
only in the cued recall, but not in the contextual recall
paradigm suggesting a possible amygdala involvement.
Interestingly, we did no observe any effect of AAV1/2-
5LO in the wild type group, suggesting a specific effect
of 5LO on the transgene.
AD is a complex neurodegenerative disease character-
ized by the presence of abundant intracellular and extra-
cellular proteinaceous deposits. Ab is a major
component of these deposits and understanding of its
production and clearance in the CNS is the focus of a
huge effort since it can help us to develop better thera-
peutic approaches. The g-secretase complex has been
identified as the rate limiting enzyme for Ab production
and, for this reason, an attractive target for AD therapy.
Interestingly, in association with an increase in the
steady state levels of three of its major protein compo-
nents we observed that their mRNAs were also signifi-
cantly elevated, suggesting a translational regulation of
these genes by 5LO. Different potential transcriptional
factor binding sites have been reported within their pro-
moter regions, and among them, a CREB binding site has
been shown to be essential for PS1 and Pen-2 transcrip-
tional regulation [13,14]. In our studies we found that
compared with the vehicle group, mice receiving AAV1/
2-5LO had a significant increase in the levels of this tran-
scription factor. By contrast, no differences between the
two groups were observed when Sp1, another transcrip-
tion factor, was assayed, suggesting a specific effect of
5LO on CREB. Taken together these findings support the
hypothesis that over-expression of neuronal 5LO by
modulating CREB levels results in an increased transcrip-
tion of the mRNAs for three of the major components of
the g-secretase complex, which ultimately is responsible
for the elevation in Ab formation and deposition.
In summary, our studies establish a functional role for
5LO in the pathogenesis and the development of the
AD-like amyloidotic phenotype, and support the hypoth-
esis that pharmacological inhibition of this enzymatic
pathway is a novel therapeutic opportunity for AD.
Methods
Construction of recombinant pAAV2/1 New MCS vector
carrying the human 5LO gene
To obtain the target gene (5LO) from the original
pcDNA2-h5LO plasmid, first we cut it with ApaI
restriction endoclease, blunt end with Klenow fragment,
and cut the obtained fragment with Hind3, which was
isolated and purified by agarose gel electrophoresis and
gel extraction kit (Qiagene). To obtain a linear vector,
we cut pAAV2/1 New MCS vector with Hind3 to gener-
ate a Hind3 cohesive end, cut the fragment with EcoRV
to generate a blunt end, then isolated and purified the
obtained vector as above described (Qiagene). Next, we
ligated 5LO DNA and the obtained linear AAV2/1 frag-
ment with quick ligase kit (Biolab), the products of the
ligation mixture were introduced into SURE2 competent
cells, and transformed cells identified by genetic selec-
tion. The recombinant plasmid was prepared from these
colonies and subjected to restriction endonuclease map-
ping to confirm the obtained DNA molecule.
Preparation of AAV2/1 vector
The packaging, purification, and titering of the recombi-
nant AAV2/1 vector expressing 5LO were performed as
previously reported [15]. Briefly, AAV2/1 vectors expres-
sing the 5LO under the control of the cytomegalovirus
enhancer/chicken actin promoter, a woodchuck post-
transcriptional regulatory element, and the bovine
growth hormone, poly(A), were generated by plasmid
transfection of HEK293T with helper plasmids for pack-
ing in capsid serotype 1. Forty-eight hours after trans-
fection, cells were harvested and lysed in the presence
of 0.5% sodium deoxycholate and 50 U/ml Benzonase
(Sigma, St. Louis, MO) by freezing-thawing cycles, and
the virus isolated by using a discontinuous iodixanol
gradient, and affinity purified on a HiTrap HQ column
(Amersham Biosciences). The genomic titer of each
virus was determined by using quantitative real-time
PCR (ABI 7900).
Injection of AAV2/1 to neonatal mice
Tg2576 mice expressing mutant APP (KM670/671NL)
gene under the control of hamster prion promoter, and
their wild type littermates were previously reported [16].
Only female mice were used in this study. The injection
procedures were performed as described previously
[17-19]. Briefly, postnatal day 0 (P0) pups were cryoa-
nesthetized on ice for 5 min. Two microliters of AAV2/
1-5LO (1.3 × 10
13 genome particles/ml) were bilaterally
injected into the cerebral ventricle of newborn mice
using a 5 μl Hamilton syringe. The injection site was 2
mm lateral and 1 mm posterior of bregma, at a depth of
1.5 mm. The needle was left in place for 1 min after the
injection was finished. A total of 5.2 × 10
13 viral genome
(4 μl) was injected into each pup’s brain. In the control
group, age matched pups were injected into the cerebral
ventricle with AAV2/1 empty vector. Pups were then
placed on a heating pad with their original nesting
material for 3-5 minutes until recovered from
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further recovery. A total of eighteen pups were used for
the study, ten were injected with AAV2/1-5LO and
eight were injected with empty vector. Animals were
then followed until they were 13-month-old, when they
first underwent to behavioral testing. During this time
mice did not display any significant difference in their
general health, growth and weight gain whether they
were randomized to the empty vector or the AAV2/15-
LO treatment groups. Two weeks after the behavioral
testing, mice were sacrificed. Macroscopic analysis of
their major organs (liver, intestine, spleen, heart, brain)
did not reveal any significant difference between the two
groups. All animal procedures were approved by the
Institutional Animal Care and Usage Committee, in
accordance with the U.S. National Institute of Health
guidelines.
Behavioral tests
All animals were pre-handled for 3 days prior to testing.
They were tested in a randomized order, and all tests
conducted by an experimenter blinded to the treatment.
Fear-conditioning
Two weeks before sacrifice, fear conditioning experi-
ments were performed following methods previously
described [20,21]. Briefly, tests were conducted in a con-
ditioning chamber (19 × 25 × 19 cm) equipped with
black methacrylate walls, transparent front door, a
speaker and grid floor (Start Fear System; Harvard
Apparatus). On day one, mice were placed into the con-
ditioning chamber and allowed free exploration for 2
min in the white noise (65 Db) before the delivery of
the conditioned stimulus (CS) tone (30 s, 90 Db, 2000
Hz) paired with a foot-shock unconditioned stimulus
(US; 2 s, 0.6 mA) through a grid floor at the end of the
tone. A total of 3 pairs of CS-US pairing with a 30 s
inter-trial interval (ITI) were presented to each animal
in the training stage. One min after the last foot-shock,
the mouse was removed from the chamber and placed
back in its home cage. The contextual fear-conditioning
stage started 24 hrs after the training phase when the
animal was put back inside the conditioning chamber
for 5 min with white noise only (65 dB). During this
time the animal’s freezing responses to the environmen-
tal context were recorded. The tone fear-conditioning
stage started 2 hrs after the contextual phase. The ani-
mal was placed back to the same chamber with different
contextual cues, including white wall, smooth metal
floor, lemon extract drops, and dimmed yellow light
conditions. After 3 min of free exploration, the mouse
was exposed to the exactly same 3 CS tones with 30 s
ITI as in the training session, without the foot-shock
and its freezing responses to the tones were recorded.
O n em i n u t ea f t e rt h el a s tt o n e ,t h em o u s ew a sb r o u g h t
back to the home cage.
Y-maze
The Y-maze apparatus consisted of three arms 32 cm
(long) ×10 cm (wide) with 26-cm walls (San Diego
Instruments). Testing was always performed in the same
room and at the same time to ensure environmental
consistency. Briefly, each mouse was placed in the cen-
ter of the Y-maze and allowed to explore freely through
the maze during a 5-min session. The sequence and
total number of arms entered were video recorded. An
entry into an arm was considered valid if all four paws
entered the arm. An alternation was defined as three
consecutive entries in three different arms (i.e. 1,2,3 or
2,3,1, etc). The percentage alternation score was calcu-
lated using the following formula: Total alternation
number/total number of entries-2)*100. Furthermore,
total number of arm entries was used as a measure of
general activity in the animals. The maze was wiped
clean with 70% ethanol between each animal to mini-
mize odor cues.
Immunoblot analyses
Proteins were extracted in EIA buffer containing 250
m MT r i sb a s e ,7 5 0m MN a C l ,5 %N P - 4 0 ,2 5m M
EDTA, 2.5% Sodium Deoxycholate, 0.5% SDS and an
EDTA-free protease inhibitor cocktail tablet (Roche
Applied Science), sonicated, centrifuged at 13,000 rpm
for 45 min at 4°C, and supernatants used for immuno-
blot analysis, as previously described [6,20]. Total pro-
tein concentration was determined by using BCA
Protein Assay Kit (Pierce, Rockford, IL). Samples were
electrophoretically separated using 10% Bis-Tris gels or
3-8% Tris-acetate gel (Bio-Rad, Richmond, CA), accord-
ing to the molecular weight of the target molecule, and
then transferred onto nitrocellulose membranes (Bio-
Rad). They were blocked with Odyssey blocking buffer
for 1 hr; and then incubated with primary antibodies
overnight at 4°C. After three washing cycles with T-
TBS, membranes were incubated with IRDye 800CW or
IRDye 680CW-labeled secondary antibodies (LI-COR
Bioscience) at 22°C for 1 hr. Signals were developed
with Odyssey Infrared Imaging Systems (LI-COR
Bioscience). Actin was always used as an internal load-
ing control. Primary antibodies used were as follows:
anti-APP N-terminal raised against amino acids 66-81
for total APP (22C11; Chemicon Int.), anti-BACE-1 (IBL
America), anti-ADAM-10 (Chemicon Int.), anti-PS1
(Cell Signaling), anti-nicastrin (Cell Signaling), anti-Pen2
(Invitrogen), anti-APH-1 (Millipore); anti-sAPPa (2B3;
IBL America); anti-sAPPb (6A1, IBL America); anti-
CTFs (EMD Biosciences Inc.); anti-neprilysin (Santa
Curz); anti-IDE N-terminal (EMD Biosciences Inc.);
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(Cell Signaling); anti-Sp1 (Cell Signaling); anti-5-LO (BD
Bioscience), anti-b actin (Santa Cruz). IRDye infrared
secondary antibodies were from LI-COR Bioscience.
Biochemical analyses
Mouse brain homogenates were sequentially extracted
first in RIPA for the Ab 1-40 and 1-42 soluble fractions,
then in formic acid for the Ab 1-40 and 1-42 insoluble
fractions, and then assayed by a sensitive sandwich
ELISA kits (WAKO Chem.) as previously described
[22,23].
Quantitative real time RT-PCR
RNA from cortex tissue of mice was extracted and puri-
fied using the RNeasy mini-kit (Qiagen), and used as
previously described [24]. Briefly, 1 μg of total RNA was
used to synthesize cDNA in a 20 μl reaction using the
RT
2 First Strand Kit for reverse transcriptase-PCR
(Super Array Bioscience). Mouse PS1, nicastrin, APH-1,
Pen-2 genes were amplified by using the corresponding
primers obtained from Super Array Bioscience. b-actin
was used as an internal control gene to normalize for
the amount of RNA. Quantitative real-time RT-PCR was
performed by using Eppendorf
® ep realplex thermal
cyclers (Eppendorf, NY). Two μl of cDNA was added to
25 μl of SYBR Green PCR Master Mix (Applied Biosys-
tems, CA). Each sample was run in duplicate, and analy-
sis of relative gene expression was done by using the 2
-
ΔΔCt method [25]. Briefly, the relative change in gene
expression was calculated by subtracting the threshold
cycle (ΔCt) of the target genes (PS1, nicastrin, APH-1
and Pen-2) from the internal control gene (b-Actin).
Based on the fact that the amount of cDNA doubles in
each PCR cycle (assuming a PCR efficiency of 100%),
t h ef i n a lf o l d - c h a n g ei ng e n ee x p r e s s i o nw a sc a l c u l a t e d
by using the following formula: relative change = 2
-ΔΔCt.
Immunohistochemistry
Immunostaining was performed as reported previously
by our group [20,23]. Serial 6-μm-thick coronal sections
were mounted on 3-aminopropyl triethoxysilane
(APES)-coated slides. Every eighth section from the
habenular to the posterior commissure (8-10 sections
per animal) was examined using unbiased stereological
principles. The sections for Ab assay were deparaffi-
nized, hydrated, pretreated with formic acid (88%) and
subsequently with 3% H2O2 in methanol. The sections
for 5-LO assay were deparaffinized, hydrated and trea-
ted with 3% H2O2 in methanol, and subsequently
retrieved antigen with citrate (10 mM). Sections were
blocked in 2% fetal bovine serum before incubation
with primary antibodies (4G8 for Ab, and monoclonal
anti-5LO antibody for 5LO,a n t i - G F A P ,a n t i - C D 4 5 )
overnight at 4°C. Subsequently, sections were incubated
with the appropriate biotinylated anti-mouse IgG (Vec-
tor Lab.) and then developed by using the avidin-biotin
complex method (Vector Lab.) with 3,3’-diaminobenzi-
dine (DAB) as a chromogen. Light microscopic images
were used to calculate the area occupied by Ab-immu-
noreactivity using the software Image-Pro Plus for Win-
dows version 5.0 (Media Cybernetics). The threshold
optical density that discriminated staining from back-
ground was determined and kept constant for all quan-
tifications. The area occupied by Ab-immunoreactivity
was measured by the software and divided by the total
area of interest to obtain the percentage area of Ab-
immunoreactivity.
Data analysis
One-way ANOVA followed by the Bonferroni’s Multiple
Comparison tests was performed using GraphPad Prism
5.0. All data are presente’d as mean ± S.E.M. Signifi-
cance was set at p < 0.05.
List of abbreviations
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